Active ingredient shortage puts Bristol-Myers Squibb cancer drug on backorder

The Food and Drug Administration reported a shortage of Bristol-Myers Squibb’s cancer drug Etopophos as of Sept. 16.

Advertisement

Etopophos is used to treat testicular cancer and small cell lung cancer. The drug is on backorder due to a raw materials shortage of one of the drug’s active ingredients.

New York City-based Bristol-Myers Squibb is working to resolve the issue as soon as possible and expects the drug to be available again September 2017.

More articles on supply chain:

Jimmy Kimmel’s EpiPen joke calls out high drug prices at Emmys
Ohio police race through anti-overdose drug supply
Sarepta’s muscular dystrophy drug to cost $300k a year

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.